Johnson & Johnson Beats Expectations & Raises Full-Year Sales Forecast

By John Heerdink LinkedIn

Recently, Johnson & Johnson (JNJ) lifted its full-year sales forecast 2019 as its cancer drugs Darzalex and Imbruvica beat the sales forecast for the second-quarter earnings. The recent approval of its cancer drug Erleada for J&J’s pharmaceuticals unit proved to help push earnings to beat expectations. Pharmaceutical sales increased 1.7% to $10.53 billion, beating the analysts’ estimates of $10.27 billion, as reported by Refinitiv. The company raised its operational sales forecast for 2019 to $83.2 billion from $82.4 billion in comparison to the prior expectation of $82 billion to $82.8 billion.

A quarterly litigation expense of $409 million was reported, lesser than the $703 million realized a year earlier.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.


J&J warns of hit from generic drugs in third quarter, shares fall

While J&J’s pharmaceuticals unit has in recent years cushioned the impact of relatively slow growth in the company’s medical device and consumer units, some of its older drugs have been hurt by competition from cheaper copies. Sales of prostate cancer treatment Zytiga fell 23% in the quarter..

Read Full Article


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us